NCT02438995View on ClinicalTrials.gov

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Carcinoma, Squamous CellCarcinoma, Squamous Cell of Head and Neck
Interventions
DRUG

Intraarterial Cetxuimab (Erbitux)

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)

Trial Locations (1)

10028

Lenox Hill Hospital, New York

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
lead

Northwell Health

OTHER